101. Joint Program In Nuclear Medicine multiple myeloma is the most common primary bone tumor. The mechanisms responsible for positive scintigraphy in multiple myeloma may be an increase in http://www.med.harvard.edu/JPNM/TF94_95/Jan17/WriteUpJan17.html

Bone Scintigraphy in Multiple Myeloma David A. Bader MD J. Stevan Nagel MD January 17, 1995 Case Presentation: A 48 year old male with no significant past medical history fell onto his right shoulder at home. A radiograph was obtained and revealed a pathologic fracture of the proximal humerus through a lytic lesion. A bone scan was requested to evaluate for fibrous dysplasia. Findings: Bone scan (63k bytes) revealed no significant activity corresponding to the known fracture site. There were several foci of anterior rib activity and an additional focus of mild to moderate increased activity in the left distal medial femur. Plain films of the ribs (95k bytes) and left femur (41k bytes) were obtained for comparison at the time of the nuclear medicine study and revealed a diffuse lytic process involving essentially all of the visible bones. The mild increased activity in the left femur ( arrow , 63k bytes) on bone scintigraphy activity was noted to correspond to periosteal reaction ( arrow , 41k bytes) at a site of pathologic fracture. All of the above imaging findings were consistent with the diagnosis of multiple myeloma. Imaging Technique: A whole body bone scan was performed following the administration of 25 mCi of Tc-99m MDP utilizing 3 hour delayed regional planar images on a Siemens body scan (dual head) with a low energy high resolution collimator.

102. Stanford Cancer Center - Multiple Myeloma | Cancer Types | Stanford Cancer Cente Yet because multiple myeloma is relatively rare it can be difficult to find a Our specialists at the Cancer Center not only treat multiple myeloma, http://cancer.stanfordhospital.com/cancerTypes/multipleMyeloma/default

Home For Patients For Health Professionals Students ... Cancer Types Multiple Myeloma Myeloma bone disease is cancer that affects certain white blood cells called plasma cells. Plasma cells produce antibodies - proteins that help the body rid itself of harmful substances. When cancer occurs, the body overproduces abnormal plasma cells called myeloma cells. Myeloma cells collect in the bone marrow and the hard outer part of the bone. A Team Approach The Stanford Cancer Center operates on a multidisciplinary approach that brings together a comprehensive, highly specialized team of board-certified physicians dedicated to tailoring special individualized treatment plans for each individual’s cancer. Backed by deep fundamental research and an extensive knowledge base in bone and blood cancer, our multidisciplinary team of experienced specialists in hematology, blood and marrow transplantation, radiology, interventional radiology, pathology, radiation oncology, medical oncology, and surgical oncology. With all your doctors working together, you can be assured that all possible treatment approaches have been considered and the one that is best for you is put into place.

103. CancerEducation: MMRF Case Studies In Multiple Myeloma - An Online CME Program F Treatment regimens for multiple myeloma are evolving because of new advances in The multiple myeloma Research Foundation has gathered the top thought http://www.cancereducation.com/cancersyspagesnb/a/mmrf/mm0206/index.cfm?rid=26

104. USATODAY.com - New Drug Shows Promise In Treating Multiple Myeloma Velcade, a new type of drug to treat the bone marrow cancer multiple myeloma, helps control the disease better than older therapies, according to an article http://www.usatoday.com/news/health/2005-06-15-cancer-drug_x.htm

OAS_listpos = "PageCount,NavBottom120x90,Top728x90,Zaplet1,FloatBottom,Bottom468x60,VerticalBanner,Poster3"; Classifieds: Cars Jobs Dating USA TODAY ... Weather Wash/Politics Washington home Washington briefs Election 2004 Government guide Health Health home Medical resources Health information Editorial/Opinion Ed/Op home Columnists Cartoons More News Top news briefs Nation briefs World briefs States ... Talk Today Marketplace Newspaper Classifieds Posted 6/15/2005 6:22 PM Today's Top News Stories Ophelia weakens to tropical storm Iraqi troops to take control of airport Police prepare to use force to clear New Orleans Additional $51.8 billion OK'd for federal aid package ... Add USATODAY.com RSS feeds E-Mail Newsletters Sign up to receive our free Daily Briefing e-newsletter and get the top news of the day in your inbox. E-mail: Select one: HTML Text Breaking News E-Mail Alerts Get breaking news in your inbox as it happens OAS_AD("VerticalBanner"); New drug shows promise in treating multiple myeloma By Liz Szabo, USA TODAY

105. CancerSource.com Multiple Myeloma Home multiple myelomaDESCRIPTION multiple myeloma (malignant tumor of plasma cells) is the most Incidence/Prevalence in USA multiple myeloma accounts for approximately 1% http://www.cancersource.com/zones/cancer.cfm?DiseaseID=20

106. Origin Of Multiple Myeloma Found In Rare Stem Cell In their studies to learn why multiple myeloma so often recurs following drug treatment, They found that this multiple myeloma stem cell looks and acts http://www.hopkinsmedicine.org/Press_releases/2003/12_03_03a.html

Send To A Friend Print This Page Media Contact: Vanessa Wasta wastava@jhmi.edu December 3, 2003 Origin of Multiple Myeloma Found in Rare Stem Cell Johns Hopkins Kimmel Cancer Center scientists have identified the cell likely to be responsible for the development of multiple myeloma, a cancer of the bone marrow that destroys bone tissue. The research, published in Blood online, suggests that therapies designed for long-term cure of the disease should target this stem cell, which, unlike other cells, can copy itself and differentiate into one or more specialized cell types. In their studies to learn why multiple myeloma so often recurs following drug treatment, the investigators uncovered a rare stem cell , occurring in just one out of every 10,000 cells or less than one percent of all myeloma cells. Working with immune system B-cells, the Johns Hopkins team found that this stem cell gives rise to the malignant bone marrow plasma cells characterized by multiple myeloma. Current treatments target the malignant plasma cells but may not be effective on the errant multiple myeloma stem cells, allowing the cancer to recur. "Most therapies today are aimed at the cancer you can see, but to cure cancer you have to go after the cells responsible for the disease, similar to how we kill a weed by getting at its roots, not just the part above the ground," explains Richard Jones, M.D., professor and director of bone marrow transplant at the Johns Hopkins Kimmel Cancer Center. "If you cut off the flower and stem of a dandelion, it may look like it has died for a period of time, but the weed eventually will grow back. If you get the root, however, the weed does not grow back."

107. BBC - Health - Conditions - Multiple Myeloma A guide to multiple myeloma. Since the cause is unknown it s not possible to prevent multiple myeloma. However, some people believe exposure to http://www.bbc.co.uk/health/conditions/myeloma1.shtml

@import url('/includes/tbenh.css') ; Home TV Radio Talk ... A-Z Index FRIDAY 9th September 2005 Text only BBC Homepage Lifestyle Health ... Help Like this page? Send it to a friend! Multiple myeloma Dr Rob Hicks Multiple myeloma is a cancer of the bone marrow. It occurs when plasma cells, the white blood cells that normally produce antibodies against infection, undergo cancerous changes and start to grow uncontrollably. In this article What are the symptoms? Who's affected? What treatment's available? Further help What are the symptoms? The uncontrolled growth of plasma cells disrupts the normal production of red blood cells, white blood cells and platelets. Excessive growth of cancerous plasma cells may damage bone causing pain. This often occurs in the lower spine and the ribs. Bone destruction can result in osteoporosis, bone fractures, and poor mobility. Uncontrolled plasma cell growth may result in: anaemia, which may cause tiredness and shortness of breath high levels of calcium, called hypercalcaemia, which may cause fatigue and tiredness recurrent, often severe, infections

108. Multiple Myeloma multiple myeloma. Inform Prevention Screening Your Illness Your Treatment Treatment Decision Tool Latest News. Connect FAQs Newsletter Archive http://www.cancerpage.com/cancers/default.asp?channel=Multiple_Myeloma

109. NCCN Multiple Myeloma Resource Line The National Comprehensive Cancer Network (NCCN), an alliance of 19 of the world s leading cancer centers, is an authoritative source of comprehensive http://www.nccn.org/professionals/myeloma_resource.asp

New Guideline: Breast Cancer Version 2.2005 Home ... Go back to previous page NCCN Multiple Myeloma Resource Line A free resource for physicians Call 866.528.NCCN (6226) from 9 AM PM EST Send an E-Mail Supported by an educational grant from the Multiple Myeloma Research Foundation The NCCN Multiple Myeloma Resource Line can help physicians integrate sophisticated advances in basic, translational, and clinical research into the day-to-day care of patients with multiple myeloma. Experts from NCCN’s Multiple Myeloma Guidelines Panels respond to specific, patient-oriented questions and provide up-to-date information about trial and laboratory results that should be considered when developing management plans aimed at achieving the best possible outcomes. NCCN Guidelines Panel members answer physician inquiries within one to two business days. Consult with NCCN panel members about multiple myeloma issues, including: Using newer agents and regimens including thalidomide, bortezomib, and lenalinomide as single agents and in combination Learning about current phase I trials of novel agents Using adjunctive treatments to control symptoms associated with this disease including current strategies for using bisphosphonates and growth factors in supportive care Integrating high-dose autologous and allogeneic stem cell transplants, maintenance and salvage therapies into treatment plans

110. Revlimid Clinical Data In Newly Diagnosed Multiple Myeloma Presented ? Celgene Corporation announced today that data evaluating clinical results on Revlimid (lenalidomide) as a new therapeutic approach for patients with http://www.news-medical.net/?id=6741

111. Multiple Myeloma: BC Cancer Agency General Information / Anatomy / Function / Statistics Myelomas are cancers of plasma cells Plasma cells are special white blood cells derived from the http://www.bccancer.bc.ca/PPI/TypesofCancer/MultipleMyeloma/

Agency Links: Home Contact Us Legal Privacy ... Types of Cancer and Sequelae Multiple Myeloma Types of Cancer and Sequelae Multiple Myeloma Diagnosis Etiology Prevention Symptoms ... Treatment Types of Cancer and Sequelae - Multiple Myeloma Print Wizard Print this Page General Information / Anatomy / Function / Statistics Myelomas are cancers of plasma cells Plasma cells are special white blood cells derived from the maturation of B (bone marrow) lymphocytes The function of plasma cells is to produce antibodies to fight infection In myeloma and other plasma cell diseases, one of the plasma cells becomes malignant and begins to proliferate independently This results in the overproduction of specific protein products called immunoglobulins (antibodies) Myelomas grow from bone marrow and affect both bone and other bone marrow cells - red, white and platelet The major problem caused by myeloma is usually bone destruction resulting in pain or collapse Other common problems include low blood counts, anemia, kidney problems and repeated infections Estimated New Cases 2000 Estimated Incidence per 100,000

112. UpToDate Patient Information: Multiple Myeloma multiple myeloma is a cancer of cells in the bone marrow called plasma cells. The current treatment options for multiple myeloma include watchful http://patients.uptodate.com/topic.asp?file=blod_dis/5717

113. Multiple Myeloma In Minnesota multiple myeloma. Summary of Minnesota Cancer Statistics*. Incidence. Mortality The causes of multiple myeloma are largely unknown. http://www.cancer.umn.edu/page/risk/multimy.html

Multiple Myeloma Summary of Minnesota Cancer Statistics* Incidence Mortality Median Age at Diagnosis (years) Lifetime Cancer Risk (per 1,000) Annual Rate (per 100,000) EAPC Annual Rate (per 100,000) EAPC Males Females Descriptive Epidemiology Risk Factors Incidence: Accounts for about 1% of all new cancers. Minnesota rate is slightly lower than national rate. There has been a 14.7% increase in national incidence from 1973 to 1995 and a slight decrease in incidence in Minnesota males from 1988 to 1996. Mortality: Mortality rates are about 80% of incidence rates, reflecting limited treatment success. Mortality rates have increased 36.6% in the U.S. from 1973 to 1995, with a similar trend seen in Minnesota. Gender: Males are almost twice as likely as females to develop multiple myeloma. Age: Risk increases with age with most cases occurring in the very elderly. Race: Greater incidence among blacks than whites; incidence lowest in Asians. SES: Higher SES associated with increased risk. Occupations/Chemicals: Farmers appear to be at increased risk for myeloma. Studies of pesticide use have yielded conflicting results but suggest some role. Exposure to paints, solvents, and benzene has been associated with myeloma but again the role is unclear. Numerous studies have associated myeloma with exposure to diesel/engine exhaust. Radiation: There is evidence that ionizing radiation is associated with myeloma; however, numerous studies have conflicting results.

114. Multiple Myeloma multiple myeloma is a malignant neoplasm of the bone marrow. In multiple myeloma, the plasma cells become malignant and abnormal. http://ww3.komotv.com/Global/story.asp?S=1230318

115. Proteasome Inhibition In The Treatment Of Multiple Myeloma: A Guide For The Prac multiple myeloma Treatment State of the Art Additional Studies and Status of Treatment in multiple myeloma multiple myeloma Research Foundation http://www.medscape.com/viewprogram/3035

Register Log In September 9, 2005 Proteasome Inhibition in the Treatment of Multiple Myeloma: A Guide for the Practicing Hematologist/Oncologist CME Faculty: Stan Winokur, MD (Moderator); Kenneth Anderson, MD; Sundar Jagannath, MD Disclosures Release Date: May 10, 2004 Valid for credit through May 10, 2005 This activity has expired. CME in this activity indicates that it was developed according to ACCME guidelines and was certified for credit by one or more accredited CME or CE providers. Medscape cannot attest to the timeliness of expired CME activities. This CME activity "Proteasome Inhibition in the Treatment of Multiple Myeloma: A Guide for the Practicing Hematologist/Oncologist" was originally offered as online streaming video program certified for CME. Contents of This CME Activity Flash Version (A multimedia presentation with synchronized audio, slides and transcript.) Note: Macromedia's Flash Player 5 plug-in is required to view the Flash version. Download the Macromedia Flash Player 5 plug-In: Multiple Myeloma Treatment: State of the Art Stan Winokur, MD (Moderator); Kenneth Anderson, MD

116. Multiple Myeloma Care - Studies Of VELCADE(R) (bortezomib) For Injection Show Em Millennium Pharmaceuticals, Inc (Nasdaq MLNM) today announced the presentation of positive clinical results for VELCADE in treating patients across the http://www.medicalnewstoday.com/medicalnews.php?newsid=22777

117. Genetic Link Possible Cause Of Multiple Myeloma In this month s Journal of Clinical Oncology, Henry T. http://www.medicalnewstoday.com/medicalnews.php?newsid=20805

118. University Of Florida Shands Cancer Center: Multiple Myeloma multiple myeloma is a cancer of plasma cells. Plasma cells are a special type Patients with multiple myeloma have increased numbers of abnormal plasma http://www.ufscc.ufl.edu/content.aspx?section=typesofcancer&id=830

119. University Of Florida Shands Cancer Center: Latest Cancer News Revlimid Delays Time to Cancer Progression in Relapsed multiple myeloma (6/1/2005) multiple myeloma Patients with Medicare can Submit Application for http://www.ufscc.ufl.edu/cancernews.aspx?section=cancernews&display=summary&cid=

120. Multiple Myeloma Although there is no cure for multiple myeloma, there are treatment Chemotherapy is effective in killing multiple myeloma cells in most patients. http://www.janssen-cilag.com/disease/detail.jhtml?itemname=multiple_myeloma&s=5

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 6     101-120 of 122    Back | 1  | 2  | 3  | 4  | 5  | 6  | 7  | Next 20